1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Biotechnology in Europe

Biotechnology in Europe

  • November 2016
  • -
  • MarketLine
  • -
  • 36 pages

Summary
Biotechnology in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Europe

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Europe

- Leading company profiles reveal details of key biotechnology market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Europe biotechnology market with five year forecasts

Reasons To Buy
- What was the size of the Europe biotechnology market by value in 2016?

- What will be the size of the Europe biotechnology market in 2021?

- What factors are affecting the strength of competition in the Europe biotechnology market?

- How has the market performed over the last five years?

- What are the main segments that make up Europe's biotechnology market?

Key Findings
The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

The European biotechnology market is expected to generate total revenues of $65.7bn in 2016, representing a compound annual growth rate (CAGR) of 5.7% between 2012 and 2016.

The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $41.8bn, equivalent to 63.6% of the market's overall value.

Europe is now only the third highest spender on RandD in the world, dropping below Asia. Although growth is forecast to continue at a strong rate, the gap in spending suggests the regions biotech industry is in need of some impetus to prevent it slipping back.

Table Of Contents

Biotechnology in Europe
Table of Contents
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
Boehringer Ingelheim GmbH
Merck and Co., Inc.
F. Hoffmann-La Roche Ltd
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine


List of Tables
Table 1: Europe biotechnology industry value: $ billion, 2012-16(e)
Table 2: Europe biotechnology industry category segmentation: $ billion, 2016(e)
Table 3: Europe biotechnology industry geography segmentation: $ billion, 2016(e)
Table 4: Europe biotechnology industry value forecast: $ billion, 2016-21
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: Boehringer Ingelheim GmbH: key facts
Table 9: Boehringer Ingelheim GmbH: key financials ($)
Table 10: Boehringer Ingelheim GmbH: key financials (€)
Table 11: Boehringer Ingelheim GmbH: key financial ratios
Table 12: Merck and Co., Inc.: key facts
Table 13: Merck and Co., Inc.: key financials ($)
Table 14: Merck and Co., Inc.: key financial ratios
Table 15: F. Hoffmann-La Roche Ltd: key facts
Table 16: F. Hoffmann-La Roche Ltd: key financials ($)
Table 17: F. Hoffmann-La Roche Ltd: key financials (CHF)
Table 18: F. Hoffmann-La Roche Ltd: key financial ratios

List of Figures
Figure 1: Europe biotechnology industry value: $ billion, 2012-16(e)
Figure 2: Europe biotechnology industry category segmentation: % share, by value, 2016(e)
Figure 3: Europe biotechnology industry geography segmentation: % share, by value, 2016(e)
Figure 4: Europe biotechnology industry value forecast: $ billion, 2016-21
Figure 5: Forces driving competition in the biotechnology industry in Europe, 2016
Figure 6: Drivers of buyer power in the biotechnology industry in Europe, 2016
Figure 7: Drivers of supplier power in the biotechnology industry in Europe, 2016
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in Europe, 2016
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in Europe, 2016
Figure 10: Drivers of degree of rivalry in the biotechnology industry in Europe, 2016
Figure 11: AstraZeneca PLC: revenues and profitability
Figure 12: AstraZeneca PLC: assets and liabilities
Figure 13: Boehringer Ingelheim GmbH: revenues and profitability
Figure 14: Boehringer Ingelheim GmbH: assets and liabilities
Figure 15: Merck and Co., Inc.: revenues and profitability
Figure 16: Merck and Co., Inc.: assets and liabilities
Figure 17: F. Hoffmann-La Roche Ltd: revenues and profitability
Figure 18: F. Hoffmann-La Roche Ltd: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • January 2017
    5 pages
  • Therapy  

  • Netherlands  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Anti-Infective Market in India

  • January 2017
    4 pages
  • Anti-Infective  

    Blood Disease  

  • India  

    United States  

View report >

Therapy Market

1 day ago

Related Market Segments :

Therapy
Biotechnology

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.